Blythe Sather’s journey from cleaning floors to achieving life-saving breakthroughs is a testament to resilience and purpose. Her career is an example of how determination and hard work can transform lives. Learn more about Blythe Sather, VP, Head of Research, Tune Therapeutics, Seattle profiled in Bizwomen https://lnkd.in/daZyHA6C #Inspiration #STEMsuccess.
Tune Therapeutics
生物技术
Durham，North Carolina 19,484 位关注者
Mastering the epigenome, unlocking complex disease.
关于我们
The vast majority of human disease is governed by the epigenome, the subtle machinery that controls the volume of gene expression in cells. Tune Therapeutics is pioneering the creation of epi-therapeutic medicines with its powerful and precise epigenomic control platform, TEMPO. Unlike genome editing, TEMPO dials the volume of gene expression up or down towards healthy levels, without breaking or permanently rewriting DNA – and it can do this in multiple genes at once. This genetic tuning approach allows us to change cell fate and function at will, unlocking the ability to reverse pathways of cancer, genetic disease and aging. Our approach effectively expands the potential reach of genetic medicine – from targeting a limited range of rare conditions, to overcoming thousands of complex and chronic diseases that currently have no curative treatment.
- 网站
-
https://www.tunetx.com
Tune Therapeutics的外部链接
- 所属行业
- 生物技术
- 规模
- 51-200 人
- 总部
- Durham，North Carolina
- 类型
- 私人持股
- 创立
- 2020
- 领域
- Biotechnology、epigenetics、cell therapy和gene therapy
地点
Tune Therapeutics员工
动态
-
Many thanks to CRISPR Medicine News for the mention of our recent CTA approval for Tune-401. Exciting time for the field!
???????? ???????????????????????? ???? ???????????????? ???????????????? ?????????? ???? ??????????-????-?????????? ???????????????????? ???????????????? ???? ?????????????? ?????????????????? ?? Tune Therapeutics has received clinical trial application approval from the New Zealand Medicines and Medical Devices Safety Authority to initiate a Phase 1b clinical trial for TUNE-401, an investigational epigenetic silencing therapy designed to treat chronic Hepatitis B. Read more in our latest clinical trial update ?? https://lnkd.in/eKxRYNUM #crisprmedicinenews #crisprmedicine #crispr #epigeneticsilencing #chronichepatitisB #chronicdisease #crisprtrial #crisprnews
-
-
Yesterday at #AASLD2024, we showcased exciting new data supporting our mission to develop a functional cure for chronic Hepatitis B Virus infection (#HBV), using Tune-401 – an epi-silencing drug now approved for clinical trial in New Zealand. This progress is a testament to the potential of epi-editing to deliver lasting impacts in common and chronic diseases. #LiverDisease #HepatitisBCure #EpigenomeEditing LEARN MORE: https://lnkd.in/erT36fgm
AASLD 2024: Tune Therapeutics Shows Near-Complete HepB Virus Repression with Tune-401 Epigenetic Silencer
businesswire.com
-
"Tune Therapeutics announced Thursday that it has received a greenlight from New Zealand regulators to start a Phase Ib study of TUNE-401 for chronic hepatitis B (HBV), which the biotech said will be the first epigenetic therapy to enter the clinic for an infectious disease." ?https://lnkd.in/e5UVwtej
First clinical test of an epigenetic HBV medicine cleared for launch
ml.firstwordpharma.com
-
REMINDER - If you are attending @AASLD ’s The Liver Meeting? 2024 in San Diego today, don’t miss Principal Scientist @Brian Cosgrove, Ph.D, on 11/18 at 8:00 am PST. Brian will be sharing exciting new data and progress around our flagship Hepatitis B program. To read the full abstract for our presentation at #TLM24, click here: https://lnkd.in/e7dV7kkK
The Liver Meeting: 2024 Abstracts | AASLD
aasld.org
-
Breaking news from Tune Therapeutics: we have just received approval from New Zealand's Medsafe to initiate a Phase 1b clinical trial for Tune-401 – our first-in-class epigenetic silencing therapy aimed at treating chronic Hepatitis B. This innovative approach targets the virus at the DNA level, offering new hope to millions of people facing long-term HBV infection. Tune-401 will be the first epigenetic therapy to enter clinical trials for an infectious disease. #Epigenetics #HepatitisB #HBV #GeneTherapy #HealthcareInnovation #Epigenetics #HepatitisB https://lnkd.in/eEvnSYS9
Tune Therapeutics Moves into Clinical Spotlight with TUNE-401: A First-in-Class Epigenetic Silencer for Hepatitis B
businesswire.com
-
Many thanks to Axios Seattle for this spotlight on our innovative, epi-silencing approach to the treatment of hepatitis B virus, offering new hope to millions living with chronic HepB infection worldwide. #GeneTherapy #HealthInnovation https://lnkd.in/ewz-c99Y
Seattle firm targets hepatitis B through gene-editing
axios.com
-
Ready to learn about epigenetic editing? Principal Scientist Brian Cosgrove, PhD was featured in the latest episode of @Technology Networks’ “Teach Me In 10” series, breaking down the basics with “Epigenetic Editing 101.” Learn about how epigenome editing is allowing exquisite control, providing exciting avenues for cell and gene therapy. Watch now: https://bit.ly/3CslIZe #EpigeneticEditing #TMI10 #TuneTx
Teach Me in 10: Accelerating Cell and Gene Therapy Development
technologynetworks.com
-
Don’t miss this engaging Technology Networks ‘Teach Me in 10’ C> development event next Weds Nov 13th, featuring our very own Brian Cosgrove, Principal Scientist at TuneTx. Brian will be heading the bill with his 10-minute ‘Epigenetic Editing 101’ talk - delivered at characteristic Cosgrove Lightspeed (TM) ?? Register FREE at the link below.
?? Excited to be a part of Teach Me in 10: Accelerating Cell and Gene Therapy Development! Our virtual event goes live next week on November 13 and it's your chance to learn from industry innovators pushing the frontiers of cell and gene therapies. ??? If you haven't registered yet, now's the time! ?? Secure your free spot here: https://bit.ly/3CslIZe Join us to explore cutting-edge insights from expert speakers who are shaping the future of this field, to name just a few: ?? Brian Cosgrove ?? John E. Milad ?? Dr. Sabrina Solt Mark your calendars, check out the agenda and don’t miss out on the chance to deepen your understanding of these transformative therapies. ?? A big thank you to our partners who make it all possible: ACROBiosystems, Eppendorf , PHC Corporation of North America, SCIEX, Sino Biological, Inc. and Refeyn?? #CellTherapy #GeneTherapy #Biotech #Pharma #PrecisionMedicine #Bioinnovation #ScienceCommunity #Academic
-
If you are attending @AASLD’s The Liver Meeting? 2024 in sunny San Diego this month, don’t miss this exciting presentation with Principal Scientist @Brian Cosgrove, Ph.D, on 11/18 at 8:00 am PST. Brian will be sharing exciting new data and progress around our flagship Hepatitis B program. To read the full abstract for our presentation at #TLM24, click here: https://lnkd.in/e7dV7kkK
The Liver Meeting: 2024 Abstracts | AASLD